Enoyl-ACP reductase inhibitors - Pipeline Insight, 2025

DelveInsight’s, “Enoyl-ACP reductase inhibitors - Pipeline Insight, 2025” report provides comprehensive insights about 2+ companies and 3+ pipeline drugs in Enoyl-ACP reductase inhibitors pipeline landscape. It covers the pipeline drug profiles, including clinical and nonclinical stage products. It also covers the therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space.

Geography Covered

• Global coverage

Enoyl-ACP reductase inhibitors Understanding

Enoyl-ACP reductase inhibitors: Overview

Enoyl-acyl carrier protein (ACP) reductases (ENRs) catalyze the last step of the elongation cycle in the synthesis of fatty acids. Fatty acid biosynthesis is essential for survival in mammals, plants, fungi and bacteria (the archaea make isoprenoid-based lipids). ENR displays an unusual diversity among organisms. The growing interest in ENRs is mainly due to the fact that a variety of both synthetic and natural antibacterial compounds are shown to specifically target their activity. In mammals, there is no homologue to ENR, which makes it an optimal candidate target for selective anti-infective drugs.

Report Highlights

• The companies and academics are working to assess challenges and seek opportunities that could influence Enoyl-ACP reductase inhibitors R&D. The therapies under development are focused on novel approaches for Enoyl-ACP reductase inhibitors.

Enoyl-ACP reductase inhibitors Emerging Drugs Chapters

This segment of the Enoyl-ACP reductase inhibitors report encloses its detailed analysis of various drugs in different stages of clinical development, including phase III, II, I, preclinical and Discovery. It also helps to understand clinical trial details, expressive pharmacological action, agreements and collaborations, and the latest news and press releases.

Enoyl-ACP reductase inhibitors Emerging Drugs

• Afabicin (Debio 1450): Debiopharm

Afabicin (Debio 1450), is the first-in class of a novel antibiotic class, fabiotics, that inhibits fatty acid synthesis in staphylococci by targeting the Fabl enzyme. It fulfills all four WHO 2020 innovativeness criteria, i.e. new chemical class, new target, new mode of action and no cross-resistance to other antibiotic classes. As a result of its potent selective activity, afabicin specifically targets staphylococci while preserving intestinal microbiota. The compound currently is in phase II research for the treatment of Bone and Joint infections (BJI) due to staphylococci. The compound is also being researched in staphylococcal acute bacterial skin and skin structure infections (ABSSSI).

Further product details are provided in the report……..

Enoyl-ACP reductase inhibitors: Therapeutic Assessment

This segment of the report provides insights about the different Enoyl-ACP reductase inhibitors drugs segregated based on following parameters that define the scope of the report, such as:

• Major Players working on Enoyl-ACP reductase inhibitors

There are approx. 2+ key companies which are developing the Enoyl-ACP reductase inhibitors. The companies which have their Enoyl-ACP reductase inhibitors drug candidates in the most advanced stage, i.e. Phase II include, Debiopharm.

• Phases

DelveInsight’s report covers around 3+ products under different phases of clinical development like

• Late-stage products (Phase III and
• Mid-stage products (Phase II and
• Early-stage products (Phase I/II and Phase I) along with the details of
• Pre-clinical and Discovery stage candidates
• Discontinued & Inactive candidates
• Route of Administration

Enoyl-ACP reductase inhibitors pipeline report provides the therapeutic assessment of the pipeline drugs by the Route of Administration. Products have been categorized under various ROAs such as

• Infusion
• Intradermal
• Intramuscular
• Intranasal
• Intravaginal
• Oral
• Parenteral
• Subcutaneous
• Topical
• Molecule Type

Products have been categorized under various Molecule types such as

• Vaccines
• Monoclonal Antibody
• Peptides
• Polymer
• Small molecule
• Product Type

Drugs have been categorized under various product types like Mono, Combination and Mono/Combination.

Enoyl-ACP reductase inhibitors: Pipeline Development Activities

The report provides insights into different therapeutic candidates in phase III, II, I, preclinical and discovery stage. It also analyses Enoyl-ACP reductase inhibitors therapeutic drugs key players involved in developing key drugs.

Pipeline Development Activities

The report covers the detailed information of collaborations, acquisition and merger, licensing along with a thorough therapeutic assessment of emerging Enoyl-ACP reductase inhibitors drugs.

Enoyl-ACP reductase inhibitors Report Insights

• Enoyl-ACP reductase inhibitors Pipeline Analysis
• Therapeutic Assessment
• Unmet Needs
• Impact of Drugs

Enoyl-ACP reductase inhibitors Report Assessment

• Pipeline Product Profiles
• Therapeutic Assessment
• Pipeline Assessment
• Inactive drugs assessment
• Unmet Needs

Key Questions

Current Scenario and Emerging Therapies:

• How many companies are developing Enoyl-ACP reductase inhibitors drugs?
• How many Enoyl-ACP reductase inhibitors drugs are developed by each company?
• How many emerging drugs are in mid-stage, and late-stage of development for the treatment of Enoyl-ACP reductase inhibitors?
• What are the key collaborations (Industry–Industry, Industry–Academia), Mergers and acquisitions, licensing activities related to the Enoyl-ACP reductase inhibitors therapeutics?
• What are the recent trends, drug types and novel technologies developed to overcome the limitation of existing therapies?
• What are the clinical studies going on for Enoyl-ACP reductase inhibitors and their status?
• What are the key designations that have been granted to the emerging drugs?

Key Players

• Debiopharm
• CrystalGenomics
• Nobelex Biotech

Key Products

• Afabicin (Debio 1450)
• CG 400549
• Debio 1452
• Debio 1454/S
• Debio 1453

Show more